* AISA THERAPEUTICS *
2005 - IDF
Évry
(near Paris)
www.aisa-tx.com Discovery, Drugs
Key words: Vascular endothelium, Inflammation, Nanomolarity, Colitis, Cystic cancer, Nutraceuticals, Anti-stress
Mission: to develop new anti-inflammatory molecules for rhumatoid arthritis, obesity, degenerative diseases, aging and metastatic spreading, based on the modulation-inhibition process in vascular permeability
Clients: pharmaceutical industry, veterinary industry
info@aisa-tx.com
Age: 4 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.-CEO: d'Alessio (Patrizia) [founder, born 1952, M.D., Ph.D., ex-Inserm]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Critt Chimie, Anvar | Turnover (M€) : n.a.
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Inflammation
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2007 .10 | Seed financing : undisclosed M€, by 2 business angels | SFIN | [2 years] |
| 2005 .10 | Company founded by Patrizia d'Alesso (Inserm), with Aisa meaning Anti Inflammatory Senescence Actives | ORGF | [0 year] | Actualisation / Updating: 08-Feb-2010 |
|
